登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.43
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
CL2242, monoclonal
Application:
immunoblotting
immunofluorescence
immunohistochemistry
immunofluorescence
immunohistochemistry
Species reactivity:
human
Citations:
3
Uniprot accession no.:
Technique(s):
immunoblotting: 1 μg/mL
immunofluorescence: 2-10 μg/mL
immunohistochemistry: 1:1000- 1:2500
immunofluorescence: 2-10 μg/mL
immunohistochemistry: 1:1000- 1:2500
产品名称
Monoclonal Anti-TUFM antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL2242, purified immunoglobulin, buffered aqueous glycerol solution
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
CL2242, monoclonal
product line
Prestige Antibodies® Powered by Atlas Antibodies
form
buffered aqueous glycerol solution
species reactivity
human
enhanced validation
RNAi knockdown
Learn more about Antibody Enhanced Validation
Quality Level
Gene Information
human ... TUFM(7284)
shipped in
dry ice
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
concentration
1 mg/mL
technique(s)
immunoblotting: 1 μg/mL
immunofluorescence: 2-10 μg/mL
immunohistochemistry: 1:1000- 1:2500
pH range
7.2-7.4
isotype
IgG1
Legal Information
Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
Application
All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.
Every Prestige Antibody is tested in the following ways:
Every Prestige Antibody is tested in the following ways:
- IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
- Protein array of 364 human recombinant protein fragments.
General description
Monoclonal Anti-TUFM Prestige Antibodies® Powered by Atlas Antibodies is developed and validated by the Human Protein Atlas (HPA) project . Each antibody is tested by immunohistochemistry against hundreds of normal and
Immunogen
Tu translation elongation factor, mitochondrial
Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence
Physical form
Phospate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
100UL pack size is provided in a solution, in PBS(phosphate-buffered saline), pH 7.2, containing 40% glycerol and 0.02% sodium azide.
Large pack size of 1ml (at 1mg/ml) is available in PBS only, purified, biocide free, carrier free and glycerol free. Order here-Request a Bulk Order /services/support/bulk-quotation-request
Large pack size of 1ml (at 1mg/ml) is available in PBS only, purified, biocide free, carrier free and glycerol free. Order here-Request a Bulk Order /services/support/bulk-quotation-request
Preparation Note
Upon arrival, mix gently and aliquot to avoid repeated freeze-thaw cycles
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
法规信息
新产品
此项目有
Ashari R Kannangara et al.
EMBO reports, 22(10), e51136-e51136 (2021-08-10)
ATG9A, the only multi-pass transmembrane protein among core ATG proteins, is an essential regulator of autophagy, yet its regulatory mechanisms and network of interactions are poorly understood. Through quantitative BioID proteomics, we identify a network of ATG9A interactions that includes
Alja Zottel et al.
Therapeutic advances in medical oncology, 12, 1758835920915302-1758835920915302 (2020-05-20)
Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form
Alja Zottel et al.
Therapeutic advances in medical oncology, 12, 1758835920915302-1758835920915302 (2020-05-20)
Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form
相关内容
Prestige Antibodies Organelle Markers
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持